Page 986 - Williams Hematology ( PDFDrive )

960 Part VII: Neutrophils, Eosinophils, Basophils, and Mast Cells Chapter 62: Eosinophils and Related Disorders 961

28. Moshkovits I, Shik D, Itan M, et al: CMRF35-like molecule 1 (CLM-1) regulates eos- 61. Tachimoto H, Burdick MM, Hudson SA, et al: CCR3-active chemokines promote rapid
inophil homeostasis by suppressing cellular chemotaxis. Mucosal Immunol 7:292–303, detachment of eosinophils from VCAM-1 in vitro. J Immunol 165:2748–2754, 2000.
2014. 62. Tomaki M, Zhao LL, Lundahl J, et al: Eosinophilopoiesis in a murine model of aller-
29. Yu C, Cantor AB, Yang H, et al: Targeted deletion of a high-affinity GATA-binding site gic airway eosinophilia: Involvement of bone marrow IL-5 and IL-5 receptor alpha.
in the GATA-1 promoter leads to selective loss of the eosinophil lineage in vivo. J Exp J Immunol 165:4040–4050, 2000.
Med 195:1387–1395, 2002. 63. Edwards BS, Curry MS, Tsuji H, et al: Expression of P-selectin at low site density pro-
30. Fukushima K, Matsumura I, Ezoe S, et al: FIP1L1-PDGFRalpha imposes eosinophil lin- motes selective attachment of eosinophils over neutrophils. J Immunol 165:404–410,
eage commitment on hematopoietic stem/progenitor cells. J Biol Chem 284:7719–7732, 2000.
2009. 64. Dang B, Wiehler S, Patel KD: Increased PSGL-1 expression on granulocytes from
31. Doyle AD, Jacobsen EA, Ochkur SI, et al: Expression of the secondary granule proteins allergic-asthmatic subjects results in enhanced leukocyte recruitment under flow
major basic protein 1 (MBP-1) and eosinophil peroxidase (EPX) is required for eosino- conditions. J Leukoc Biol 72:702–710, 2002.
philopoiesis in mice. Blood 122:781–790, 2013. 65. Woltmann G, McNulty CA, Dewson G, et al: Interleukin-13 induces PSGL-1/P-select-
32. Farahi N, Singh NR, Heard S, et al: Use of 111-Indium-labeled autologous eosino- in-dependent adhesion of eosinophils, but not neutrophils, to human umbilical vein
phils to establish the in vivo kinetics of human eosinophils in healthy subjects. Blood endothelial cells under flow. Blood 95:3146–3152, 2000.
120:4068–4071, 2012. 66. Johansson MW: Activation states of blood eosinophils in asthma. Clin Exp Allergy
33. Lukawska JJ, Livieratos L, Sawyer BM, et al: Real-time differential tracking of human 44:482–498, 2014.
neutrophil and eosinophil migration in vivo. J Allergy Clin Immunol 133:233–239.e1, 67. Bahaie NS, Hosseinkhani MR, Ge XN, et al: Regulation of eosinophil trafficking by
2014. SWAP-70 and its role in allergic airway inflammation. J Immunol 188:1479–1490, 2012.
34. Takatsu K, Kouro T, Nagai Y: Interleukin 5 in the link between the innate and acquired 68. Ha SG, Ge XN, Bahaie NS, et al: ORMDL3 promotes eosinophil trafficking and activa-
immune response. Adv Immunol 101:191–236, 2009. tion via regulation of integrins and CD48. Nat Commun 4:2479, 2013.
35. van Rensen EL, Stirling RG, Scheerens J, et al: Evidence for systemic rather than pulmo- 69. Pope SM, Zimmermann N, Stringer KF, et al: The eotaxin chemokines and CCR3
nary effects of interleukin-5 administration in asthma. Thorax 56:935–940, 2001. are fundamental regulators of allergen-induced pulmonary eosinophilia. J Immunol
36. Leckie MJ, ten Brinke A, Khan J, et al: Effects of an interleukin-5 blocking monoclonal 175:5341–5350, 2005.
antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. 70. Neighbour H, Boulet LP, Lemiere C, et al: Safety and efficacy of an oral CCR3 antag-
Lancet 356:2144–2148, 2000. onist in patients with asthma and eosinophilic bronchitis: A randomized, placebo-
37. Culley FJ, Brown A, Girod N, et al: Innate and cognate mechanisms of pulmonary eos- controlled clinical trial. Clin Exp Allergy 44:508–516, 2014.
inophilia in helminth infection. Eur J Immunol 32:1376–1385, 2002. 71. Simon HU, Yousefi S, Schranz C, et al: Direct demonstration of delayed eosinophil
38. Martin C, Al-Qaoud KM, Ungeheuer MN, et al: IL-5 is essential for vaccine-induced apoptosis as a mechanism causing tissue eosinophilia. J Immunol 158:3902–3908, 1997.
protection and for resolution of primary infection in murine filariasis. Med Microbiol 72. Anwar AR, Moqbel R, Walsh GM, et al: Adhesion to fibronectin prolongs eosinophil
Immunol 189:67–74, 2000. survival. J Exp Med 177:839–843, 1993.
39. Humbert M, Corrigan CJ, Kimmitt P, et al: Relationship between IL-4 and IL-5 mRNA 73. Flood-Page PT, Menzies-Gow AN, Kay AB, et al: Eosinophil’s role remains uncertain as
expression and disease severity in atopic asthma. Am J Respir Crit Care Med 156: anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit
704–708, 1997. Care Med 167:199–204, 2003.
40. Domachowske JB, Bonville CA, Easton AJ, et al: Pulmonary eosinophilia in mice 74. Brode S, Farahi N, Cowburn AS, et al: Interleukin-5 inhibits glucocorticoid-mediated
devoid of interleukin-5. J Leukoc Biol 71:966–972, 2002. apoptosis in human eosinophils. Thorax 65:1116–1117, 2010.
41. Fulkerson PC, Schollaert KL, Bouffi C, et al: IL-5 triggers a cooperative cytokine net- 75. Robertson NM, Zangrilli JG, Steplewski A, et al: Differential expression of TRAIL and
work that promotes eosinophil precursor maturation. J Immunol 193:4043–4052, 2014. TRAIL receptors in allergic asthmatics following segmental antigen challenge: Evi-
42. Finotto S, Neurath MF, Glickman JN, et al: Development of spontaneous airway dence for a role of TRAIL in eosinophil survival. J Immunol 169:5986–5996, 2002.
changes consistent with human asthma in mice lacking T-bet. Science 295:336–338, 76. Adachi T, Alam R: The mechanism of IL-5 signal transduction. Am J Physiol
2002. 275:C623–C633, 1998.
43. Neurath MF, Finotto S, Glimcher LH: The role of Th1/Th2 polarization in mucosal 77. Dewson G, Cohen GM, Wardlaw AJ: Interleukin-5 inhibits translocation of Bax to the
immunity. Nat Med 8:567–573, 2002. mitochondria, cytochrome c release, and activation of caspases in human eosinophils.
44. Rothenberg ME, Mishra A, Collins MH, et al: Pathogenesis and clinical features of eos- Blood 98:2239–2247, 2001.
inophilic esophagitis. J Allergy Clin Immunol 108:891–894, 2001. 78. Letuve S, Druilhe A, Grandsaigne M, et al: Involvement of caspases and of mitochon-
45. Ozdemir C, Akdis M, Akdis CA: T regulatory cells and their counterparts: Masters of dria in Fas ligation-induced eosinophil apoptosis: Modulation by interleukin-5 and
immune regulation. Clin Exp Allergy 39:626–639, 2009. interferon-gamma. J Leukoc Biol 70:767–775, 2001.
46. McHugh RS, Shevach EM: The role of suppressor T cells in regulation of immune 79. Letuve S, Druilhe A, Grandsaigne M, et al: Critical role of mitochondria, but not cas-
responses. J Allergy Clin Immunol 110:693–702, 2002. pases, during glucocorticosteroid-induced human eosinophil apoptosis. Am J Respir
47. Levings MK, Sangregorio R, Sartirana C, et al: Human CD25(+)CD4(+) T suppressor Cell Mol Biol 26:565–571, 2002.
cell clones produce transforming growth factor beta, but not interleukin 10, and are 80. Oh J, Malter JS: Pin1-FADD interactions regulate Fas-mediated apoptosis in activated
distinct from type 1 T regulatory cells. J Exp Med 196:1335–1346, 2002. eosinophils. J Immunol 190:4937–4945, 2013.
48. Curotto de Lafaille MA, Lafaille JJ: CD4(+) regulatory T cells in autoimmunity and 81. Ben Baruch-Morgenstern N, Shik D, Moshkovits I, et al: Paired immunoglobulin-like
allergy. Curr Opin Immunol 14:771–778, 2002. receptor A is an intrinsic, self-limiting suppressor of IL-5-induced eosinophil develop-
49. Yazdanbakhsh M, Kremsner PG, van Ree R: Allergy, parasites, and the hygiene hypoth- ment. Nat Immunol 15:36–44, 2014.
esis. Science 296:490–494, 2002. 82. Robinson DS, Damia R, Zeibecoglou K, et al: CD34(+)/interleukin-5Ralpha messenger
50. Wills-Karp M, Santeliz J, Karp CL: The germless theory of allergic disease: Revisiting RNA+ cells in the bronchial mucosa in asthma: Potential airway eosinophil progeni-
the hygiene hypothesis. Nat Rev Immunol 1:69–75, 2001. tors. Am J Respir Cell Mol Biol 20:9–13, 1999.
51. Umetsu DT, Akbari O, Dekruyff RH: Regulatory T cells control the development of 83. Corry DB, Rishi K, Kanellis J, et al: Decreased allergic lung inflammatory cell egres-
allergic disease and asthma. J Allergy Clin Immunol 112:480–487; quiz 488, 2003. sion and increased susceptibility to asphyxiation in MMP2-deficiency. Nat Immunol
52. Akdis CA, Blaser K: Mechanisms of interleukin-10-mediated immune suppression. 3:347–353, 2002.
Immunology 103:131–136, 2001. 84. Martin C, Burdon PC, Bridger G, et al: Chemokines acting via CXCR2 and CXCR4
53. Finlay CM, Walsh KP, Mills KH: Induction of regulatory cells by helminth parasites: control the release of neutrophils from the bone marrow and their return following
Exploitation for the treatment of inflammatory diseases. Immunol Rev 259:206–230, senescence. Immunity 19:583–593, 2003.
2014. 85. Muessel MJ, Scott KS, Friedl P, et al: CCL11 and GM-CSF differentially use the Rho
54. Wardlaw A: Eosinophil density: What does it mean? Clin Exp Allergy 25:1145–1149, GTPase pathway to regulate motility of human eosinophils in a three-dimensional
1995. microenvironment. J Immunol 180:8354–8360, 2008.
55. Mishra A, Hogan SP, Brandt EB, et al: Enterocyte expression of the eotaxin and inter- 86. Daubeuf F, Frossard N: Eosinophils and the ovalbumin mouse model of asthma. Meth-
leukin-5 transgenes induces compartmentalized dysregulation of eosinophil traffick- ods Mol Biol 1178:283–293, 2014.
ing. J Biol Chem 277:4406–4412, 2002. 87. Lambrecht BN, Hammad H: The immunology of asthma. Nat Immunol 16:45–56, 2014.
56. Nussbaum JC, Van Dyken SJ, von Moltke J, et al: Type 2 innate lymphoid cells control 88. Gwinn WM, Damsker JM, Falahati R, et al: Novel approach to inhibit asthma-mediated
eosinophil homeostasis. Nature 502:245–248, 2013. lung inflammation using anti-CD147 intervention. J Immunol 177:4870–4879, 2006.
57. Bochner BS: Road signs guiding leukocytes along the inflammation superhighway. 89. Uller L, Mathiesen JM, Alenmyr L, et al: Antagonism of the prostaglandin D2 recep-
J Allergy Clin Immunol 106:817–828, 2000. tor CRTH2 attenuates asthma pathology in mouse eosinophilic airway inflammation.
58. Rosenberg HF, Phipps S, Foster PS: Eosinophil trafficking in allergy and asthma. Respir Res 8:16, 2007.
J Allergy Clin Immunol 119:1303–1310; quiz 1311–1312, 2007. 90. Sturm EM, Schratl P, Schuligoi R, et al: Prostaglandin E2 inhibits eosinophil trafficking
59. Mjosberg J, Eidsmo L: Update on innate lymphoid cells in atopic and non-atopic through E-prostanoid 2 receptors. J Immunol 181:7273–7283, 2008.
inflammation in the airways and skin. Clin Exp Allergy 44:1033–1043, 2014. 91. Yousefi S, Gold JA, Andina N, et al: Catapult-like release of mitochondrial DNA by
60. Palframan RT, Collins PD, Williams TJ, et al: Eotaxin induces a rapid release of eosino- eosinophils contributes to antibacterial defense. Nat Med 14:949–953, 2008.
phils and their progenitors from the bone marrow. Blood 91:2240–2248, 1998. 92. Lacy P, Moqbel R: Eosinophil cytokines. Chem Immunol 76:134–155, 2000.

Kaushansky_chapter 62_p0947-0964.indd 961 9/21/15 10:56 AM